PMID: 8975874Dec 1, 1996Paper

The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors

Journal of Leukocyte Biology
M H KershawM J Smyth

Abstract

Chimeric receptors that redirect effector cell function to tumor cells or virus-infected cells have received much attention. Given the high affinity of Fc(epsilon)RI for immunoglobulin E (IgE) and low serum IgE levels, redirection of effector cells using Fc(epsilon) receptor may provide a novel, versatile, and effective anti-tumor strategy. We have used a mouse perforin 5'-promoter to express a single-chain human Fc(epsilon) receptor in the mouse cytotoxic T lymphocyte cell line, CTLL-R8. Upon ligation of the chimeric Fc(epsilon) receptors by IgE, a signal for effector function is transmitted via the intracellular domain of CD3zeta. Selection in G418-containing medium produced CTLLR8 transfectant clones that: (1) expressed chimeric Fc(epsilon) receptor as determined by flow cytometry; (2) bound human IgE antibodies with high affinity as determined by Scatchard analysis; (3) specifically rosetted IgE-coated SRBC; (4) lysed target cells in IgE-mediated ADCC and reverse ADCC assays; and (5) retarded tumor growth in a Winn assay. Therefore these chimeric Fc(epsilon) receptors can effectively redirect cytotoxicity to tumor cells. Future efforts will assess the versatility and efficacy of these IgE-binding chimeric receptors to redir...Continue Reading

Citations

May 23, 2001·Leukemia·V F Van TendelooZ N Berneman
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sophia N KaragiannisHannah J Gould
Mar 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·P K DarcyM J Smyth
May 23, 2001·Leukemia·V F Van TendelooZ N Berneman
Nov 30, 2006·Annual Review of Immunology·Ann M LeenAaron E Foster
Oct 21, 2006·Human Gene Therapy·Michele W L TengPhillip K Darcy
Mar 8, 2011·Expert Opinion on Biological Therapy·Dario SangioloWanda Piacibello
Jan 16, 2014·MAbs·Debra H JosephsSophia N Karagiannis
Dec 24, 2011·Cancer Immunology, Immunotherapy : CII·Tracy R DanielsManuel L Penichet
Mar 1, 2006·Expert Opinion on Biological Therapy·Aaron E Foster, Cliona M Rooney
Mar 14, 2017·Therapeutic Advances in Gastroenterology·Komal ThindMitesh J Borad
May 1, 2018·Canadian Journal of Gastroenterology & Hepatology·Xianliang ChengYunqi Zhao
Jun 6, 2000·Advanced Drug Delivery Reviews·Z Eshhar, C J Fitzer-Attas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.